About xeris biopharma holdings inc - XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
XERS At a Glance
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street
Chicago, Illinois 60607
| Phone | 1-844-445-5704 | Revenue | 291.85M | |
| Industry | Biotechnology | Net Income | 554.00K | |
| Sector | Health Technology | 2025 Sales Growth | 43.716% | |
| Fiscal Year-end | 12 / 2026 | Employees | 435 | |
| View SEC Filings |
XERS Valuation
| P/E Current | 1,887.50 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2,453.125 |
| Price to Sales Ratio | 4.646 |
| Price to Book Ratio | 95.313 |
| Price to Cash Flow Ratio | 47.37 |
| Enterprise Value to EBITDA | 39.987 |
| Enterprise Value to Sales | 5.15 |
| Total Debt to Enterprise Value | 0.172 |
XERS Efficiency
| Revenue/Employee | 670,908.046 |
| Income Per Employee | 1,273.563 |
| Receivables Turnover | 5.717 |
| Total Asset Turnover | 0.808 |
XERS Liquidity
| Current Ratio | 2.193 |
| Quick Ratio | 1.566 |
| Cash Ratio | 1.013 |
XERS Profitability
| Gross Margin | 81.699 |
| Operating Margin | 8.531 |
| Pretax Margin | 0.19 |
| Net Margin | 0.19 |
| Return on Assets | 0.153 |
| Return on Equity | N/A |
| Return on Total Capital | 0.204 |
| Return on Invested Capital | 0.228 |
XERS Capital Structure
| Total Debt to Total Equity | 1,885.441 |
| Total Debt to Total Capital | 94.963 |
| Total Debt to Total Assets | 65.685 |
| Long-Term Debt to Equity | 1,839.915 |
| Long-Term Debt to Total Capital | 92.67 |